You are here

bladder cancer

FDA limits first-line bladder cancer labels for Keytruda, Tecentriq

FDA limits first-line bladder cancer labels for Keytruda, Tecentriq

Biopharma Dive

Flag link:

FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq

Biopharma Dive

clinical trials

Flag link:

Merck's Keytruda shows up its rivals with NICE backing in bladder cancer

Merck's Keytruda shows up its rivals with NICE backing in bladder cancer

Fierce Pharma

Flag link:

How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment

How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment

Motley Fool

prostate cancer

Merkel cell carcinoma

metastatic non-small cell lung cancer

metastatic breast cancer

Flag link:

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo

Fierce Pharma

PARP inhibitors

Flag link:

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte

Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte

Endpoints

Bristol-Myers Squibb

cervical cancer

Flag link:

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Fierce Pharma

Flag link:

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

Fierce Pharma

clinical trials

Flag link:

ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals

Fierce Pharma

Flag link:

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure

BioPharma Dive

Flag link:

Has Merck Lucked Into A $10 Billion Drug?

Has Merck Lucked Into A $10 Billion Drug?

Forbes

non-small cell lung cancer

Flag link:

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

Endpoints

clinical trials

Flag link:

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Move over, AstraZeneca. Pfizer and Merck KGaA are the newest bladder cancer drugmakers in town

Fierce Pharma

Flag link:

AstraZeneca's New Drug: Too Little, Too Late?

AstraZeneca's New Drug: Too Little, Too Late?

Seeking Alpha

Flag link:

Roche's Tecentriq wins FDA OK as first-line treatment in bladder cancer

Roche's Tecentriq wins FDA OK as first-line treatment in bladder cancer

Fierce Pharma

Flag link:

Merck KGaA, Pfizer get priority review for bladder cancer drug

Merck KGaA, Pfizer get priority review for bladder cancer drug

Yahoo/Reuters

Flag link:

Checkpoint inhibitors set to face off in bladder cancer

Checkpoint inhibitors set to face off in bladder cancer

BioPharma Dive

Bristol-Myers Squibb

Flag link:

FDA approves Bristol-Myers' Opdivo for bladder cancer

FDA approves Bristol-Myers' Opdivo for bladder cancer

Yahoo/Reuters

Bristol-Myers Squibb

Flag link:

Taris Biomedical closes enrollment in phase Ib trial for drug-device combo

Taris Biomedical closes enrollment in phase Ib trial for drug-device combo

Mass Device

drug-device combos

Flag link:

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

Endpoints

Flag link:

Pages